Fitocanabinoides Derivados de Cannabis sativa na Psoríase: Efeitos Sobre Inflamação e Hiperproliferação Epidérmica

Mariana Adverse; Júlia Guimarães; Júlia Fonsêca; Evelynn Melo; Gustavo Diniz

doi:10.36489/nursing.2026v32i341p22548-22565

Authors

Mariana Adverse Centro Universitário de Belo Horizonte https://orcid.org/0009-0006-0933-2775
Júlia Guimarães Centro Universitário Euro-Americano https://orcid.org/0009-0008-3652-8030
Júlia Fonsêca Universidade Nove de Julho https://orcid.org/0000-0003-1189-3003
Evelynn Melo Universidade Federal do Rio de Janeiro https://orcid.org/0009-0004-8621-1171
Gustavo Diniz Faculdade Asgard

DOI:

https://doi.org/10.36489/nursing.2026v32i341p22548-22565

Keywords:

Psoriasis, Cannabinoids, Cannabidiol, Inflammation, Cell Proliferation

Abstract

Objetivo: Analisar criticamente os efeitos dos fitocanabinoides derivados de Cannabis sativa sobre a inflamação e a hiperproliferação epidérmica na psoríase.

Método: Realizou-se revisão integrativa da literatura, com buscas nas bases PubMed/MEDLINE e PubMed Central, complementadas por rastreamento manual das referências dos estudos selecionados, abrangendo publicações de 2016 a 2026, com prioridade para o período de 2021 a 2026 e inclusão excepcional de um estudo seminal anterior. Foram selecionados estudos in vitro, pré-clínicos e clínicos relacionados aos mecanismos moleculares, à resposta inflamatória e à homeostase epidérmica.

Resultados: O canabidiol, composto mais investigado, modula receptores canabinoides e alvos não clássicos, atenua as vias NF-κB e JAK/STAT, reduz mediadores do eixo IL-23/IL-17 e exerce efeitos antiproliferativos, antioxidantes e favoráveis à diferenciação terminal. Contudo, predominam evidências experimentais, enquanto os estudos clínicos permanecem escassos, heterogêneos e demonstram benefícios discretos.

Conclusão: Os fitocanabinoides apresentam potencial terapêutico, mas sua aplicação clínica requer ensaios controlados, com formulações padronizadas, biomarcadores teciduais e avaliação prolongada da eficácia e da segurança.

Author Biographies

Mariana Adverse, Centro Universitário de Belo Horizonte

Graduanda em Medicina no Centro Universitário de Belo Horizonte (UNIBH)

Júlia Guimarães, Centro Universitário Euro-Americano

Graduanda em Medicina no Centro Universitário Euro-Americano (UNIEURO)

Júlia Fonsêca, Universidade Nove de Julho

Graduanda em Medicina na Universidade Nove de Julho (UNINOVE)

Evelynn Melo, Universidade Federal do Rio de Janeiro

Mestre pela Universidade Federal do Rio de Janeiro (UFRJ)

References

Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis. Lancet. 2021;397(10281):1301-15.

Pagano C, Ciaglia E, Coppola L, Lopardo V, Raimondo A, Giuseppe M, et al. Cannabidiol exerts multitarget immunomodulatory effects on PBMCs from individuals with psoriasis vulgaris. Front Immunol. 2024;15:1373435.

Wroński A, Jarocka-Karpowicz I, Stasiewicz A, Skrzydlewska E. Phytocannabinoids in the pharmacotherapy of psoriasis. Molecules. 2023;28(3):1192.

Yoo EH, Lee JH. Cannabinoids and their receptors in skin diseases. Int J Mol Sci. 2023;24(22):16523.

Kim MS, Lee JH, Kim SW, Bang CH. Cannabidiol alleviates imiquimod-induced psoriasis by inhibiting JAK2-STAT3 in a mouse model. Biomedicines. 2024;12(9):2084.

Tortolani D, Di Meo C, Standoli S, Ciaramellano F, Kadhim S, Hsu E, et al. Rare phytocannabinoids exert anti-inflammatory effects on human keratinocytes via the endocannabinoid system and MAPK signaling pathway. Int J Mol Sci. 2023;24(3):2721.

Puaratanaarunkon T, Sittisaksomjai S, Sivapornpan N, Pongcharoen P, Chakkavittumrong P, Ingkaninan K, et al. Topical cannabidiol-based treatment for psoriasis: a dual-centre randomized placebo-controlled study. J Eur Acad Dermatol Venereol. 2022;36(9):e718-20.

Roongpisuthipong W, Klangjareonchai T, Kurathong S, Roongpisuthipong A. Efficacy and safety of cannabidiol oil in psoriasis: a randomized, double-blind, placebo-controlled trial. J Dermatolog Treat. 2026;37(1):2604448.

Jang Y, Jeong S, Mok BR, Son SJ, Ryu JS, Son WS, et al. Cannabidiol mediates epidermal terminal differentiation and redox homeostasis through aryl hydrocarbon receptor (AhR)-dependent signaling. J Dermatol Sci. 2023;109(2):61-70.

Di Meo C, Tortolani D, Standoli S, Angelucci CB, Fanti F, Leuti A, et al. Effects of rare phytocannabinoids on the endocannabinoid system of human keratinocytes. Int J Mol Sci. 2022;23(10):5430.

Di Meo C, Tortolani D, Standoli S, Ciaramellano F, Angelucci BC, Tisi A, et al. Cannabinol modulates the endocannabinoid system and shows TRPV1-mediated anti-inflammatory properties in human keratinocytes. Biofactors. 2025;51(1):e2122.

Fumagalli M, Martinelli G, Paladino G, Rossini N, Ciriello U, Nicolaci V, et al. Beyond cannabidiol: the contribution of Cannabis sativa phytocomplex to skin anti-inflammatory activity in human skin keratinocytes. Pharmaceuticals (Basel). 2025;18(5):647.

Jarocka-Karpowicz I, Biernacki M, Wroński A, Gęgotek A, Skrzydlewska E. Cannabidiol effects on phospholipid metabolism in keratinocytes from patients with psoriasis vulgaris. Biomolecules. 2020;10(3):367.

Tsiogkas SG, Apostolopoulou K, Papagianni ED, Mavropoulos A, Dardiotis E, Zafiriou E, et al. Cannabidiol mediates in vitro attenuation of proinflammatory cytokine responses in psoriatic disease. Cannabis Cannabinoid Res. 2024;9(1):134-46.

Wójcik P, Garley M, Wroński A, Jabłońska E, Skrzydlewska E. Cannabidiol modifies the formation of NETs in neutrophils of psoriatic patients. Int J Mol Sci. 2020;21(18):6795.

Charoenying T, Lomwong K, Boonkrong P, Kruanamkam W. Therapeutic potential of topical cannabis for the treatment of psoriasis: a preliminary clinical evaluation of two different formulations. J Curr Sci Technol. 2024;14(1):6.

Vincenzi C, Tosti A. Efficacy and tolerability of a shampoo containing broad-spectrum cannabidiol in the treatment of scalp inflammation in patients with mild to moderate scalp psoriasis or seborrheic dermatitis. Skin Appendage Disord. 2020;6(6):355-61.

Sermsaksasithorn P, Asawanonda P, Phutrakool P, Ondee T, Chariyavilaskul P, Payungporn S, et al. Efficacy and safety of cannabis transdermal patch for alleviating psoriasis symptoms: protocol for a randomized controlled trial (CanPatch). Med Cannabis Cannabinoids. 2024;7(1):99-110.

Rendon A, Schäkel K. Psoriasis pathogenesis and treatment. Int J Mol Sci. 2019;20(6):1475.

Wilkinson JD, Williamson EM. Cannabinoids inhibit human keratinocyte proliferation through a non-CB1/CB2 mechanism and have a potential therapeutic value in the treatment of psoriasis. J Dermatol Sci. 2007;45(2):87-92.

Łuczaj W, Dobrzyńska I, Wroński A, Domingues MR, Domingues P, Skrzydlewska E. Cannabidiol-mediated changes to the phospholipid profile of UVB-irradiated keratinocytes from psoriatic patients. Int J Mol Sci. 2020;21(18):6592.

Szachowicz-Petelska B, Łuczaj W, Wroński A, Jastrząb A, Dobrzyńska I. The differential effect of cannabidiol on the composition and physicochemical properties of keratinocyte and fibroblast membranes from psoriatic patients and healthy people. Membranes (Basel). 2021;11(2):111.

Gęgotek A, Atalay S, Wroński A, Markowska A, Skrzydlewska E. Cannabidiol decreases metalloproteinase activity and normalizes angiogenesis factor expression in UVB-irradiated keratinocytes from psoriatic patients. Oxid Med Cell Longev. 2021;2021:7624389.

Zamansky M, Yariv D, Feinshtein V, Ben-Shabat S, Sintov AC. Cannabidiol-loaded lipid-stabilized nanoparticles alleviate psoriasis severity in mice: a new approach for improved topical drug delivery. Molecules. 2023;28(19):6907.